The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 640-650

  Zudaire, Enrique ^a   Cuesta, Natalia ^b   Murty, Vundavalli ^c   Woodson, Karen ^a   Adams, Lisa ^a   Gonzalez, Nieves ^d   Martínez, Alfredo ^e   Narayan, Gopeshwar ^c   Kirsch, Ilan ^a   Franklin, Wilbur ^f   Hirsch, Fred ^f   Birrer, Michael ^a   Cuttitta, Frank ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e INSTITUTO CAJAL   (Spain)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL TRANSPLANTATION; COLON CANCER; CONTROLLED STUDY; DNA HYPERMETHYLATION; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, ARYL HYDROCARBON; RNA, SMALL INTERFERING;

EID: 38849171927     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30024     Document Type: Article

References (51)

1. Burbach, K.M., Poland, A., and Bradfield, C.A. 1992. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. U. S. A. 89:8185-8189.
2. Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U. S. A. 92:5510-5514.
3. Hoffman, E.C., et al. 1991. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 252:954-958.
4. Mimura, J., Ema, M., Sogawa, K., and Fujii-Kuriyama, Y. 1999. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 13:20-25.
5. Reyes, H., Reisz-Porszasz, S., and Hankinson, O. 1992. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science. 256:1193-1195.
6. Denison, M.S., and Nagy, S.R. 2003. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 43:309-334.
7. Kasai, A., et al. 2006. High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res. 66:7143-7150.
8. Moennikes, O., et al. 2004. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 64:4707-4710.
9. Andersson, P., et al. 2002. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. U. S. A. 99:9990-9995.
10. Koliopanos, A., et al. 2002. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene. 21:6059-6070.
11. Shimada, T., et al. 2002. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis. 23:1199-1207.
12. Mitra, A.B., et al. 1995. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J. Natl. Cancer Inst. 87:742-745.
13. Xu, S.F., Peng, Z.H., Li, D.P., Qiu, G.Q., and Zhang, F. 2003. Refinement of heterozygosity loss on chromosome 5p15 in sporadic colorectal cancer. World J. Gastroenterol. 9:1713-1718.
14. Wang, V.W., Bell, D.A., Berkowitz, R.S., and Mok, S.C. 2001. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res. 61:4169-4174.
15. Bohm, M., Kleine-Besten, R., and Wieland, I. 2000. Loss of heterozygosity analysis on chromosome 5p defines 5p13-12 as the critical region involved in tumor progression of bladder carcinomas. Int. J. Cancer. 89:194-197.
16. Peralta, R.C., et al. 1998. Distinct regions of frequent loss of heterozygosity of chromosome 5p and 5q in human esophageal cancer. Int. J. Cancer. 78:600-605.
17. Wieland, I., et al. 1996. Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene. 12:97-102.
18. Kanno, Y., Takane, Y., Izawa, T., Nakahama, T., and Inouye, Y. 2006. The inhibitory effect of aryl hydrocarbon receptor repressor (AhRR) on the growth of human breast cancer MCF-7 cells. Biol. Pharm. Bull. 29:1254-1257.
19. Kim, S.H., et al. 2007. Association between susceptibility to advanced stage endometriosis and the genetic polymorphisms of aryl hydrocarbon receptor repressor and glutathione-S-transferase T1 genes. Hum. Reprod. 22:1866-1870.
20. Knudson, A.G. 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer. 1:157-162.
21. Arias-Pulido, H., Narayan, G., Vargas, H., Mansukhani, M., and Murty, V.V. 2002. Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions. Mol. Cancer. 1:3.
22. Smiraglia, D.J., et al. 2002. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene. 21:3909-3916.
23. Donehower, L.A., et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:215-221.
24. Downward, J. 2005. RNA interference libraries prove their worth in hunt for tumor suppressor genes. Cell. 121:813-815.
25. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
26. Soule, H.D., et al. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50:6075-6086.
27. Evan, G.I., and Vousden, K.H. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342-348.
28. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
29. Stanbridge, E.J. 1990. Identifying tumor suppressor genes in human colorectal cancer. Science. 247:12-13.
30. White, R.L. 1998. Tumor suppressing pathways. Cell. 92:591-592.
31. Jones, P.A., and Laird, P.W. 1999. Cancer epigenetics comes of age. Nat. Genet. 21:163-167.
32. Murty, V.V., et al. 1994. Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene. 9:2245-2251.
33. Ku, W.H., et al. 1997. Genomic deletion and p53 inactivation in cervical carcinoma. Int. J. Cancer. 72:270-276.
34. Luft, F., Gebert, J., Schneider, A., Melsheimer, P., and von Knebel Doeberitz, M. 1999. Frequent allelic imbalance of tumor suppressor gene loci in cervical dysplasia. Int. J. Gynecol. Pathol. 18:374-380.
35. Tate, P.H., and Bird, A.P. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3:226-231.
36. Baba, T., et al. 2001. Structure and expression of the Ah receptor repressor gene. J. Biol. Chem. 276:33101-33110.
37. Haarmann-Stemmann, T., et al. 2007. Analysis of the transcriptional regulation and molecular function of the aryl hydrocarbon receptor repressor in human cell lines. Drug Metab. Dispos. 35:2262-2269.
38. Mulero-Navarro, S., et al. 2005. Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J. Biol. Chem. 280:28731-28741.
39. Elferink, C.J. 2003. Aryl hydrocarbon receptor-mediated cell cycle control. Prog. Cell Cycle Res. 5:261-267.
40. Hsia, D.A., et al. 2003. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160:753-767.
41. Cavallaro, U., and Christofori, G. 2004. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer. 4:118-132.
42. Hu, L., et al. 2004. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 23:298-302.
43. Narayan, G., et al. 2003. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer. 2:24.
44. Koul, S., et al. 2002. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol. Cancer. 1:8.
45. Maines-Bandiera, S.L., Kruk, P.A., and Auersperg, N. 1992. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am. J. Obstet. Gynecol. 167:729-735.
46. Manzano, R.G., et al. 2002. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene. 21:4435-4447.
47. Hendricks, D.T., Taylor, R., Reed, M., and Birrer, M.J. 1997. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57:2112-2115.
48. Waltenberger, J., et al. 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-26995.
49. Quandt, K., Frech, K., Karas, H., Wingender, E., and Werner, T. 1995. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23:4878-4884.
50. Giaever, I., and Keese, C.R. 1993. A morphological biosensor for mammalian cells. Nature. 366:591-592.
51. Guedez, L., et al. 2003. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am. J. Pathol. 162:1431-1439.